Therapeutic evidence shows encouraging tumour retention and safety profiles for agents such as [<sup>177</sup>Lu]Lu-FAP-2286 and [<sup>90</sup>Y]Y-FAPI-46, while α-emitting radiotracers (e.g., [<sup>225</sup>Ac]Ac-FAPI-04) demonstrate potent antitumor effects in preclinical models. This evidence concerns the gene FAP and neoplasm.